<div id="readability-page-1"><div><p>Guardant Health (GH) has just posted its FY 2025 numbers with Q4 revenue of US$281.3 million, a basic EPS loss of US$1.00 and net income loss of US$128.5 million, set against a trailing twelve month revenue base of US$982.0 million and a TTM EPS loss of US$3.32. Over recent quarters the company has seen revenue move from US$201.8 million in Q4 FY 2024 to US$281.3 million in Q4 FY 2025. Quarterly basic EPS losses have ranged between US$0.74 and US$1.00, and TTM net income losses have remained above US$400 million, putting the spotlight firmly on how quickly revenue growth can work through to more efficient margins.</p> <p>See our full analysis for Guardant Health.</p><p>With the headline figures on the table, the next step is to see how these results line up with the prevailing narratives about Guardant Health's growth potential, risk profile and path toward better margins.</p> <p>See what the community is saying about Guardant Health</p> <figure><img height="476" src="https://imageproxy.pbkrs.com/https://images.simplywall.st/company/9931ee85-f6ce-4e16-a029-7898a0ecf7dd/chart/revenue-and-expenses-breakdown/query-ZGF0ZT0yMDI2LTA1LTA5?x-oss-process=image/auto-orient,1/interlace,1/resize,w_1440,h_1440/quality,q_95/format,jpg" width="746" original-src="https://imageproxy.pbkrs.com/https://images.simplywall.st/company/9931ee85-f6ce-4e16-a029-7898a0ecf7dd/chart/revenue-and-expenses-breakdown/query-ZGF0ZT0yMDI2LTA1LTA5"/><figcaption>NasdaqGS:GH Revenue &amp; Expenses Breakdown as at May 2026</figcaption></figure> <h2>Nearly US$1b in TTM revenue, but losses still above US$400m</h2> <ul> <li>On a trailing twelve month basis, Guardant Health generated US$982.0 million in revenue while recording a net income loss of US$416.3 million and a TTM basic EPS loss of US$3.32.</li> <li>Bulls point out that analysts are forecasting revenue growth of about 20.9% per year, faster than the 11.4% expected for the broader US market. However, the latest TTM loss of US$416.3 million and quarterly net income losses between US$92.7 million and US$128.5 million highlight how far profitability still is from those growth expectations.     <ul> <li>Consensus narrative leans on strong demand for blood based cancer diagnostics and AI powered analytics to support high double digit revenue growth, which lines up with the 20.9% forecast growth rate.</li> <li>At the same time, the company remains unprofitable on trailing figures and is not forecast to reach profitability within three years, so the current loss profile needs to be weighed carefully against any long term growth story.</li> </ul> </li> </ul> <h2>Premium 12.5x P/S and a DCF fair value of US$170.75</h2> <ul> <li>The stock trades on a P/S of 12.5x compared with about 1.2x for the US healthcare industry and 1.3x for close peers, while a DCF fair value of US$170.75 and a consensus analyst target of US$128.33 both sit above the current share price of US$92.26.</li> <li>Supporters of the bullish view argue that strong top line trends can justify that premium. Even so, the combination of a 12.5x P/S multiple and ongoing TTM losses means the valuation is sensitive to any change in growth expectations.     <ul> <li>Bullish analysts are assuming revenue growth well above the 20.9% consensus pace in their upside scenarios, which helps frame why a DCF fair value of US$170.75 still screens above today’s price.</li> <li>Critics highlight that even with analyst upside to US$128.33 from US$92.26, the stock already trades at a substantial premium to industry and peer P/S ratios, so any disappointment on growth or margins could affect how investors view that gap.</li> </ul> </li> </ul><p> On these numbers, it is easy to see why some investors focus on the optimistic case for long term growth while others worry about what needs to go right to support such a rich multiple.<strong>🐂 Guardant Health Bull Case</strong></p><h2>Unprofitable today and bears watching cash burn</h2> <ul> <li>Guardant Health is unprofitable on trailing twelve month metrics, with a TTM net loss of US$416.3 million, negative shareholders’ equity, and quarterly net income losses above US$90 million through FY 2025.</li> <li>Skeptics point out that forecasts do not show a return to profitability over the next three years and that negative equity adds balance sheet risk on top of recurring losses, even though revenue is expected to grow at 20.9% per year.     <ul> <li>Bearish narratives emphasize that ongoing cash burn, including planned free cash flow burn of around US$225 million to US$235 million in 2025, leaves little room for setbacks if revenue growth or reimbursement trends fall short.</li> <li>Against that backdrop, the premium 12.5x P/S multiple and negative equity position mean any prolonged period of losses could keep the focus on funding needs rather than just the topline growth story.</li> </ul> </li> </ul><p> Skeptical investors are therefore paying close attention to how quickly losses narrow relative to the pace of revenue growth and the company’s current balance sheet position.<strong>🐻 Guardant Health Bear Case</strong></p><h2>Next Steps</h2> <p>To see how these results tie into long-term growth, risks, and valuation, check out the full range of community narratives for Guardant Health on Simply Wall St. Add the company to your watchlist or portfolio so you'll be alerted when the story evolves.</p> <p>Split views on Guardant Health after these results are understandable. Consider reviewing the numbers yourself and deciding where you stand, starting with its 3 key rewards and 2 important warning signs</p> <h2>See What Else Is Out There</h2> <p>Guardant Health still records sizeable losses, negative equity and ongoing cash burn, so the current premium P/S multiple leaves little margin for error.</p> <p>If you want ideas where balance sheet strength is front and center instead of ongoing losses, check out the solid balance sheet and fundamentals stocks screener (44 results) to find sturdier candidates quickly.</p> <p><em> This article by Simply Wall St is general in nature. <strong>We provide commentary based on historical data         and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice.</strong> It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your         financial situation. We aim to bring you long-term focused analysis driven by fundamental data.         Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material.         Simply Wall St has no position in any stocks mentioned.</em></p><div><h3><strong>New: </strong>Manage All Your Stock Portfolios in One Place</h3><p>We've created the <strong>ultimate portfolio companion</strong> for stock investors, <strong>and it's free.</strong></p><p>• Connect an unlimited number of Portfolios and see your total in one currency<br/>• Be alerted to new Warning Signs or Risks via email or mobile<br/>• Track the Fair Value of your stocks<br/></p><p>Try a Demo Portfolio for Free</p></div></div></div>

IDNA

<p>Guardant Health (GH) reported FY 2025 Q4 revenue of $281.3 million, with a basic EPS loss of $1.00 and a net income loss of $128.5 million. Despite a revenue increase from $201.8 million in Q4 FY 2024, the company continues to face significant losses, totaling $416.3 million on a trailing twelve month basis. Analysts forecast a 20.9% annual revenue growth, but profitability remains elusive. The stock trades at a premium P/S of 12.5x, raising concerns about valuation sensitivity to growth expectations. Investors are divided on the company's long-term growth potential versus its ongoing cash burn and balance sheet risks.</p>

Simplywall

Guardant Health

VanEck Biotech ETF

iShares Genomics Immunology and Healthcare ETF

ALPS Medical Breakthrough

iShares US Medical Devices

Ark Genomic Revolution ETF

Proshares Ultra Nasdaq Biotech

First Trust NYSE Arca Biotech Index Fd

Health Care Select Sector SPDR

iShares US Healthcare Providers

Invesco Biotechnology & Genome ETF

Direxion S&P Biotech Bull 3X

iShares Biotechnology ETF

SPDR S&P Biotech

Guardant Health (GH) Earnings Spotlight Revenue Growth Versus Persistent Losses Challenges Premium Valuation Narratives